Glioblastoma multiforme (GBM) is a highly aggressive, complex, and devastating form of brain cancer, effecting hundreds of people each day. We believe it is our duty to accelerate progress against this disease so we launched the Defeat GBM Research Collaborative in 2013 with the intent to double the 5 year survival rate of GBM patients. This comes at a time when collaboration is becoming the norm and the abundance of genomic data is accelerating diagnostic, prognostic, and therapeutic progress.
Oligo Research Fund
Oligodendroglioma (oligo) is a relatively rare brain tumor representing about 6% of gliomas, with a diagnosis rate of about 1,150 patients a year in the U.S. alone. Critical research is required to deliver oligo patients new therapies that are more durable and extend their lives. In order to make effective, targeted therapies a reality it is essential to identify and understand the molecular drivers of the tumor’s genesis and maintenance, as well as resistance.
Our new pediatric initiative, Project Impact, will leverage increases in knowledge gained from earlier funded research efforts, and develop a program that can address critical barriers to progress within the drug discovery and development pipeline through an integrated approach to advance research toward new treatments for pediatric brain tumor patients.
The Community Research Fund allows contributors to pool donations to support research on a specific type of tumor. This program leverages a team of highly experienced, nationally-recognized scientific experts, working with National Brain Tumor Society staff, to determine the best investment strategy for each fund.
From the Blog
October 30, 2014
Creating Meaningful Change, With a Little Help From our Friends
There are only four FDA-approved therapies to treat brain tumors. And in the last 17 years there have been approximately 75 potential new drugs that have failed during the clinical trial process to prove they are safe and effective for patients, while only three that have won FDA approval. That is a 25:1 failure ratio. […]Read more |
October 28, 2014
A New “America’s Neuro-Oncologist” at the National Cancer Institute
Yesterday, it was announced that Dr. Mark R. Gilbert, MD, has been named Chief of the Neuro-Oncology Branch (NOB) at the National Institutes of Health (NIH), within the Center for Cancer Research of the National Cancer Institute (NCI). In this position, Dr. Gilbert – previously Deputy Chairman of the Department of Neuro-Oncology at MD Anderson […]Read more |
October 22, 2014
Hope for GBM Patients
Recent news and conversations across social media has churned up a lot of concern and fear over glioblastoma multiforme (GBM) tumors. And while we know all too well it’s the deadliest form of brain cancer with dismal survival rates, we also want the public to know how the National Brain Tumor Society is working to […]Read more |